Frontotemporal Disorders Treatment Market Size, Share, Outlook By 2021-2028

(YourDigitalWall Editorial):- Abbeville, Louisiana Nov 10, 2021 (Issuewire.com) – Market Overview

The Global Frontotemporal Disorders Treatment Market is expected to grow at a high CAGR of 7.2% during the forecasting period (2021-2028).

Frontotemporal disorder, commonly known as Pick disease, is a form of dementia that is caused by a family of brain disorders known as frontotemporal lobar degeneration (FTLD). Frontotemporal dementia is a rare type of dementia that causes behaviour and language problems. Dementia is associated with disorders of mental abilities caused by some changes and damage in the brain and affects the front and sides of the brain. Dementia mostly affects people aged over 65 years, but frontotemporal dementia tends to start at a younger age. The common cases are diagnosed in people aged between 45-65 years, although it can also affect younger or older people. The mutation of different genes, such as VCP, CHMP2B, Tau gene, PGRN gene, FUS genes, TARDBP, and C9ORF72 gene are likely to cause frontotemporal disorders. Some of the common symptoms of frontotemporal disorders include dysarthria, perseveration, aphasia, utilization behavior, social disinhibition, emotional changes, social-interpersonal changes, apraxia, gait disorder, dystonia, among others.

The diagnosis of frontotemporal disorders is mainly made through genetic tests, blood tests, and physical examinations. These tests help to understand similar conditions, genetic mutation tests, and brain imaging changes in temporal and frontal lobes. Antipsychotics and antidepressants and antipsychotic medications can help in curing the symptoms of frontotemporal disorders. Increasing clinical trials and investment support from giant pharmaceutical companies to develop a treatment for this disorder is expected to drive market growth during the forecast period.

Download free sample:https://www.datamintelligence.com/download-sample/frontotemporal-disorders-treatment-market

Market Dynamics

The global frontotemporal disorders treatment market growth is majorly driven by certain factors such as the rising prevalence of dementia and other frontotemporal disorders, increasing drug development grants, and funding by the government as well as non-government organizations.

The increasing prevalence of target diseases and the growing geriatric population suffering from these disorders are expected to drive the market growth. As per the World Health Organization, about 50 Mn people have dementia, and there are around 10 Mn new cases annually, which is anticipated to boost the industry growth. Generally, the onset of this disorder occurs in the age range of 50 to 60 years and affected 50,000 to 60,000 Americans in 2011. Frontotemporal dementia accounts for 2-5% of the overall dementia cases. The prevalence of dementia is projected to be triple by 2050. As per the Dementia Statistics Organization, the number of people living with dementia is projected to increase by 204% from 50 million in 2018 to 152 million by 2050. The increasing number of dementia cases will further increase the cases of frontotemporal dementia, which is expected to drive more demand for frontotemporal disorders treatment drugs and medications.

Also, the rising government support and funding for research activities to find the treatment of target disease is expected to drive the growth of the market. Several organizations are involved in developing new medications, including the National Institute of Health (NIH), Alzheimer’s Association, and National Institute on Aging. In 2019, the NIH spent around US$ 387 million on research projects for Alzheimer’s Disease-Related Dementias (ADRD). These initiatives are expected

to boost market growth over the forecast period. However, a lack of awareness towards the target disease in a developing country may hamper the market growth.

Segment Analysis

By Drug Class

• Cognitive Enhancers
• Antipsychotics
• Aripiprazole
• Paliperidone
• Olanzepine
• Risperidone
• Quetiapine
• Ziprasidone
• Antidepressants
• Bupropion
• Fluvoxamine
• Citalopram
• Fluoxetine
• Mitrazepine
• Paroxetine
• Sertraline
• CNS stimulants
• Others

By Indication

• Primary Progressive Aphasia (PPA)
• Semantic PPA, Agrammatic PPA
• Logopenic PPA)
• Motor Decline (Corticobasal syndrome (CBS)
• Progressive supranuclear palsy (PSP)

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

Geographical Analysis

North America region is dominating the global frontotemporal disorders treatment market accounting for the largest market share in 2019, owing to a large presence of advanced healthcare facilities and infrastructure in developed countries, such as the United States. Also, the rising prevalence of frontotemporal disorders in this region is also driving the growth of the market. For instance, according to the National Institute of Neurological Disorders and Stroke, Alzheimer’s disease alone, as one dementia disorder, affects over 5 million people in the United States. The toll on individuals, society, and caregivers is enormous and is expected to increase as the population ages. Frontotemporal dementia falls under rare diseases or orphan indications. In the United States, around 30,000 to 40,000 patients are suffering from frontotemporal disorders. Treatment of frontotemporal disorders falls under the Orphan Drug Act of 1983 as orphan drug indications are those which affect less than 200,000 people in the U.S. along with similar legislation in Europe. Orphan drug designation to FTD allows the continuation of clinical trials and development of a drug with commercial incentives, prioritizing consultation by FDA on clinical studies and reduction in regulatory fees.

The Asia-Pacific frontotemporal disorders market is expected to grow at the fastest CAGR over the forecast period due to the high prevalence of the target diseases due to the growing geriatric population base and increasing disposable income level.

View full report:https://www.datamintelligence.com/research-report/frontotemporal-disorders-treatment-market

Related reports:

Cancer Treatment Drugs Market

Allergy Treatment Market